Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) Current ratio
Globus Medical, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 4.3×, up 0.0× from fiscal 2025 (4.3×). Over the past ten years it has ranged from 2.5× (fiscal 2024) to 6.8× (fiscal 2020); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.3× | 67.62% |
| FY2024 | 2.5× | (47.89%) |
| FY2023 | 4.9× | (20.96%) |
| FY2022 | 6.2× | 0.14% |
| FY2021 | 6.2× | (9.34%) |
| FY2020 | 6.8× | 10.24% |
| FY2019 | 6.2× | (5.95%) |
| FY2018 | 6.6× | (1.55%) |
| FY2017 | 6.7× | 3.64% |
| FY2016 | 6.4× | (2.39%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 4.3× | (7.06%) |
| Jun 2026 | 4.6× | 1.45% |
| Mar 2026 | 4.6× | 6.85% |
| Dec 2025 | 4.3× | 3.25% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PEN Penumbra, Inc. compare | 5.9× |
| TXG 10x Genomics compare | 5.7× |
| GKOS Glaukos Corporation compare | 4.6× |
| GMED Globus Medical, Inc. | 4.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| PODD Insulet Corporation compare | 2.5× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.1× |
| BRKR Bruker Corporation compare | 1.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on GMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement